Lung cancer cells have differential signaling responses to KRAS inhibitor treatment

Geriatric emergency departments associated with lower Medicare expenditures
1 March 2021
Deciphering the genetics behind eating disorders
1 March 2021

Lung cancer cells have differential signaling responses to KRAS inhibitor treatment

Genetic alterations of the KRAS gene are some of the most common mutations in lung cancer patients, but unfortunately these patients have few effective treatment options. Drugs that target the G12C mutation in KRAS have shown some activity in lung cancer; however, alternative signaling pathways are often activated that bypass the KRAS inhibitor, resulting in drug resistance. In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.

Comments are closed.